Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ompenaclid - Inspirna

Next Previous
Drug Profile

Ompenaclid - Inspirna

Alternative Names: RGX-202; RGX-202-01

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rgenix
  • Developer Inspirna
  • Class Antineoplastics; Guanidines; Propionic acids; Small molecules
  • Mechanism of Action Creatine transporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • No development reported Biliary cancer; Gastric cancer; Intestinal cancer; Oesophageal cancer; Pancreatic cancer

Most Recent Events

  • 31 Mar 2025 Inspirna completes a phase-I/II clinical trials in Colorectal cancer (Monotherapy, Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03597581)
  • 13 Jan 2025 Merck plans a clinical trial for Colorectal cancer (Combination therapy, Metastatic disease, First-line therapy)
  • 13 Sep 2024 Efficacy and adverse event data from a phase Ib/II trial in Colorectal cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top